Study on the efficacy and safety of Remimazolam in one lung ventilation.

Not Applicable

Recruiting

• Conditions: ung Neoplasms; remimazolam, one lung ventilation, HPV, hypoxic pulmonary vasoconstriction; D008175

• Registration Number: JPRN-jRCT1031210446
• Lead Sponsor: Hirotsugu Okamoto

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-11-24
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

Patients aged 20 years and older undergoing lung surgery with one-lung ventilation and general anesthesia with epidural

Exclusion Criteria

If the research subject refuses to cooperate in the research.
Contraindications to the use of anesthetics.
If the subject has a disease that affects HPV.
In the case of a procedure in which one lung ventilation is frequently released intraoperatively, such as surgery for pneumothorax.
Patients with longitudinal tumors in the supine position who may require only short periods of one-lung ventilation.
If the patient is scheduled to receive intraoperative cardiopulmonary ventilation.
Patients with severe chronic lung disease (1 sec rate 50%or less, % lung capacity less than 80%)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To analyze the frequency and degree of hypoxemia in the remimazolam and propofol groups.<br>Values of arterial blood oxygen saturation, partial pressure of arterial blood oxygen, inspiratory oxygen concentration, and P/F ratio (partial pressure of arterial blood oxygen/inspiratory oxygen concentration) during anesthesia, immediately before, 30 minutes after, and 1 hour after the start of one-lung ventilation.